Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
September 30, 2026 38.38M
June 30, 2026 34.81M
March 31, 2026 32.20M
December 31, 2025 31.16M
September 30, 2025 29.38M
June 30, 2025 27.79M
March 31, 2025 25.49M
December 31, 2024 25.56M
September 30, 2024 25.85M
June 30, 2024 25.00M
March 31, 2024 25.32M
December 31, 2023 22.34M
September 30, 2023 20.91M
June 30, 2023 21.92M
March 31, 2023 19.55M
December 31, 2022 20.97M
September 30, 2022 26.29M
June 30, 2022 25.91M
Date Value
March 31, 2022 27.38M
December 31, 2021 25.06M
September 30, 2021 19.29M
June 30, 2021 17.10M
March 31, 2021 17.21M
December 31, 2020 19.92M
September 30, 2020 27.83M
June 30, 2020 39.87M
March 31, 2020 53.92M
December 31, 2019 60.44M
September 30, 2019 60.41M
June 30, 2019 55.76M
March 31, 2019 45.11M
December 31, 2018 40.65M
September 30, 2018 34.84M
June 30, 2018 29.69M
March 31, 2018 25.22M
December 31, 2017 20.17M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Ligand Pharmaceuticals, Inc. 23.09M
MBX Biosciences, Inc. 101.27M
ANI Pharmaceuticals, Inc. 50.60M
Corcept Therapeutics, Inc. 241.72M
Veru, Inc. 11.76M